| Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients (NCT05396118) | Rigshospitalet, Denmark | 2022-05-18 |
| Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm (NCT05113355) | Peking Union Medical College Hospital | 2021-11-17 |
| Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma (NCT05076786) | Peking Union Medical College Hospital | 2021-10-27 |
| PrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANEC (NCT06400654) | European Institute of Oncology | 2021-07-05 |
| A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 (NCT04524208) | Karsten Gavenis | 2021-03-01 |
| Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas (NCT04701307) | M.D. Anderson Cancer Center | 2021-02-01 |
| Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma (NCT04705519) | Peking University | 2021-01-05 |
| Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC (NCT06369181) | Fudan University | 2021-01-01 |
| A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) (NCT04471727) | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2020-12-14 |
| Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) (NCT04464122) | University of Roma La Sapienza | 2020-09-14 |
| Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary (NCT04325425) | Centre Hospitalier Universitaire Dijon | 2020-09-01 |
| Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma (NCT03901378) | Ochsner Health System | 2019-10-02 |
| Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract (NCT04069299) | H. Lee Moffitt Cancer Center and Research Institute | 2019-09-25 |
| Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms (NCT03834701) | Catholic University of the Sacred Heart | 2019-09-01 |
| Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors (NCT03647163) | Vyriad, Inc. | 2019-04-09 |
| Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (NCT03591731) | Intergroupe Francophone de Cancerologie Thoracique | 2019-01-02 |
| Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer (NCT03728361) | Dwight Owen | 2018-12-31 |
| Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors (NCT03600233) | TaiRx, Inc. | 2018-12-15 |
| Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma (NCT03837977) | The Christie NHS Foundation Trust | 2018-11-13 |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors (NCT03517488) | Xencor, Inc. | 2018-07-10 |
| Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors (NCT03290079) | H. Lee Moffitt Cancer Center and Research Institute | 2017-12-15 |
| Avelumab in G3 NEC (NCT03278405) | Sunnybrook Health Sciences Centre | 2017-11-15 |
| Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma (NCT03279614) | Peking University | 2017-09-01 |
| Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer (NCT03110978) | M.D. Anderson Cancer Center | 2017-06-26 |
| TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors (NCT03079440) | Asan Medical Center | 2017-05-15 |
| Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma (NCT03168607) | Peking University | 2017-05-02 |
| Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma (NCT03168594) | Peking University | 2017-04-29 |
| CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas (NCT03387592) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2017-03-06 |
| Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors (NCT03074513) | M.D. Anderson Cancer Center | 2017-03-03 |
| PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers (NCT02936323) | Tarveda Therapeutics | 2016-12-08 |
| Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans (NCT02970786) | Rigshospitalet, Denmark | 2016-11-01 |
| The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S] (NCT02688894) | Samsung Medical Center | 2016-06-10 |
| Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin (NCT02687958) | Gruppo Oncologico Italiano di Ricerca Clinica | 2015-05-01 |
| Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery (NCT02315625) | National Cancer Institute (NCI) | 2015-04-08 |
| RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide (NCT02270567) | Wren Laboratories LLC | 2015-02-01 |
| An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours (NCT02236910) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2014-07-01 |
| The Aim of This Study is to Demonstrat That Vacuum-assisted Closure Versus Conventional Wound Closure Enables to Diminish Local Complications After Lymph Node Dissection in Patients With Metastatic Skin Tumors (NCT04583605) | Central Hospital, Nancy, France | 2014-01-01 |
| P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome (NCT01886287) | H. Lee Moffitt Cancer Center and Research Institute | 2013-12-01 |
| 68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs) (NCT01879657) | Radio Isotope Therapy of America | 2013-03-01 |
| Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer (NCT01642251) | National Cancer Institute (NCI) | 2012-09-28 |
| Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers (NCT01121939) | SCRI Development Innovations, LLC | 2010-05-01 |
| 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer (NCT01396382) | Vanderbilt-Ingram Cancer Center | 2010-03-01 |
| Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma (NCT00607113) | M.D. Anderson Cancer Center | 2008-01-01 |
| Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma (NCT00663429) | Callisto Pharmaceuticals | 2007-11-01 |
| Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma (NCT00388063) | Callisto Pharmaceuticals | 2006-10-01 |
| Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy (NCT00363051) | Novartis Pharmaceuticals | 2006-06-01 |
| RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma (NCT00113360) | M.D. Anderson Cancer Center | 2005-01-01 |
| Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases (NCT00019786) | National Institutes of Health Clinical Center (CC) | 1999-08-01 |
| Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma (NCT00193531) | SCRI Development Innovations, LLC | 1998-12-01 |
| Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy (NCT00003514) | Burzynski Research Institute | |